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Abstract
Sulindac sulfide, a metabolite of the nonsteroidal antiin-
( )flammatory drug NSAID sulindac sulfoxide, is effec-
tive at reducing tumor burden in both familial adenoma-
tous polyposis patients and in animals with colorectal
cancer. Another sulindac sulfoxide metabolite, sulindac
sulfone, has been reported to have antitumor properties
without inhibiting cyclooxygenase activity. Here we re-
port the effect of sulindac sulfone treatment on the
growth of colorectal carcinoma cells. We observed that
sulindac sulfide or sulfone treatment of HCA-7 cells led
to inhibition of prostaglandin E production. Both sulin-2
dac sulfide and sulfone inhibited HCA-7 and HCT-116
cell growth in vitro. Sulindac sulfone had no effect on
the growth of either HCA-7 or HCT-116 xenografts,
whereas the sulfide derivative inhibited HCA-7 growth
in vivo. Both sulindac sulfide and sulfone inhibited
colon carcinoma cell growth and prostaglandin produc-
tion in vitro, but sulindac sulfone had no effect on the
growth of colon cancer cell xenografts in nude mice.
Keywords: sulindac, sulindac sulfide, sulindac sulfone, chemoprevention, colorec-
tal cancer.
Introduction
Colorectal cancer remains a significant health concern for
much of the industrialized world. Diagnosis often occurs at a
late stage in the progression of this disease, which reduces
the likelihood of effective treatment. Current treatment
strategies often involve a combination of surgical resection
and adjuvant therapy. Because of the unsatisfactory out-
come of existing treatment methods, much emphasis has
been placed on developing new treatment and prevention
strategies.
Numerous epidemiologic studies indicate that chronic
use of low-dose nonsteroidal antiinflammatory drugs
( ) [ ]NSAIDs are chemopreventive for colorectal cancer 1,2 .
NSAIDs cause regression of existing polyps in familial ade-
( )nomatous polyposis FAP patients and reduce the tumor
[ ]burden in animal models of colorectal cancer 3–6 . NSAIDs
( )inhibit the activity of the cyclooxygenases COX , which are
( )key enzymes in prostaglandin PG production. Unfortu-
nately, prolonged NSAID use can result in side effects such
as gastrointestinal ulceration and bleeding. It is widely be-
lieved that this ulcerogenic activity is due to chronic inhibi-
tion of PG production via COX-1 inhibition in the gastric
mucosa. Accordingly, researchers have tried to identify
NSAID derivatives that retain antitumor activity but do not
affect PG production in gastric mucosa.
Sulindac sulfoxide is a prodrug that is reduced in vivo to
sulindac sulfide or oxidized to sulindac sulfone. The sulfide
derivative effectively inhibits the COX enzymes. Sulindac
sulfone does not interfere with COX activity when applied to
( ) [ ]the recombinant enzyme in vitro data not shown 7 .
Studies in which colorectal cancer cell lines were treated
with high doses of either sulfide or sulfone indicated that
both derivatives can induce apoptosis and alter proliferation
[ ]rates 7 . There is evidence that sulindac sulfone can induce
apoptosis in cell lines that do not express either COX-1 or
[ ]COX-2 7 . Accordingly, the mechanism of action of this
compound, at the effective doses, is independent of any
possible interaction with COX in these cells. Because sulin-
dac sulfone does not appear to inhibit the COX activity and
can induce apoptosis in colorectal cancer cell lines indepen-
dent of COX expression, it held some promise as a potential
chemopreventive agent for colorectal cancer with improved
safety over NSAIDS.
It has previously been reported that sulindac sulfone is
capable of reducing the incidence, multiplicity and tumor
( )burden in the azoxymethane AOM rat model of colorectal
[ ]cancer 8 . In another animal model, the Min mouse, sulin-
dac sulfone had no effect on polyp number or size whereas
sulindac sulfide was quite effective in causing polyp regres-
[ ]sion 4 . In both studies, drug treatment was initiated before
a lesion had developed. In this study we tested the hypothe-
sis that sulindac sulfone can inhibit the growth of highly
malignant colorectal carcinoma cells in both in vitro and in
vivo tumor models. These studies may help to clarify the
potential in vivo effectiveness of sulindac sulfone in colorec-
tal cancer treatment.
Materials and Methods
Reagents
Sulindac sulfide and sulindac sulfone were obtained from
( )Merck and Co, Rahway, NJ, and dimethyl sulfoxide DMSO
Abbreviations: NSAID, nonsteroidal antiinflamatory drug; FAP, familial adenoma-
tous polyposis; PGE , prostaglandin E ; COX, cyclooxygenases; AOM,2 2
azoxymethane; DMSO, dimethyl sulfoxide; FGN-1, sulindac sulfone.
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( )EM Science, Gibbstown, NJ was used as the solvent.
Concentrated drug stocks were diluted in Dulbecco’s modi-
( ) (fied Eagle’s medium DMEM GIBCO-BRL, Grand Island,
)NY before addition to cell cultures. The DMSO concentra-
tion in cultures was kept at 0.1%, and the purity of sulindac
sulfone was verified by NMR.
Prostaglandin Measurement
Subconfluent cell cultures were treated with the indicated
compound for 24 hours. One hour before harvesting, arachi-
donate was added to the media to a final concentration of
10 mmol/L along with fresh drug. Eicosanoids were quanti-
fied in media from cell incubations by using stable isotope
dilution techniques with gas chromatography negative ion
chemical ionization-mass spectrometry, as previously de-
[ ]scribed 9,10 . The limits of sensitivity for detection of either
PGE , PGD , PGF , thromboxane B , or 6-ketoPGF is 42 2 2 2 1
pg/mL. PG levels were standardized to the number of
viable cells.
In Vitro Growth Assays:
Either 2.5 = 104 cells/well for HCT-116, or 5 = 104
cells per well for HCA-7 cells were suspended in 0.5 mL of
(1:2 diluted Matrigel Collaborative Biomedical Products,
)Bedford, MA . The cell /Matrigel mixture was plated into
24-well plates and treated with the indicated dose of sulin-
dac sulfide or sulfone. Media was replaced every other day
with media containing the appropriate amount of drug.
Western Blotting
Immunoblot analysis of cell protein lysates were per-
[ ]formed as previously described 11 . Briefly, cells were
( )lysed for 30 minutes in radio imunoprecipitation buffer RIPA
( [ ]1 = phosphate-buffered saline PBS , 1% Nonidet P-40,
Figure 1. Sulindac sulfide and sulfone decrease PG levels in HCA-7
cells. HCA-7 cells were plated in 100mm dishes and grown to 70%
confluence, then treated for 23 hours with sulindac sulfide, sulindac
( )sulfone, or vehicle DMSO . One hour before harvesting media, the cells
were washed with PBS and media containing 10 mmol/L arachidonic
acid and the indicated dose of drug was added. PGE levels were2
determined by using gas chromatography negative ion chemical ioniza-
tion-mass spectrometry and standardized to cell number. Error bars
represent the standard error of the mean.
Figure 2. Sulindac sulfide and sulfone do not affect the expression of
( )COX-1 or COX- 2 in HCA-7 cells. Whole cell lysates 50 mg from
HCA-7 cells treated for 24 hours with either sulindac sulfide or sulfone
were resolved by SDS-PAGE. Proteins were transferred to PVDF mem-
( ) (branes and blotted with either COX- 2 top panel or COX-1 bottom
)panel specific antisera, then imaged by ECL, followed by autoradiog-
raphy. For COX- 2, 50 mg of HCA-7 or HCT -116 cell lysates served as
( ) ( )COX- 2 positive q and negative - controls, respectively. For COX -1,
50 mg of MC - 26 or HCT -116 cell lysates served as COX -1 positive
( ) ( )q and negative - controls, respectively.
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
[ ]) ( )SDS and then clarified cell lysates 50 mg were dena-
tured and fractionated by 10% SDS-polyacrylamide gel
( )electrophoresis PAGE . The proteins were transferred to
( )polyvinylidene flouride PVDF membranes after elec-
trophoresis. The filters were blocked 3 hours in BLOTTO
(0.15 mol/L NaCl; 10 mmol/L Tris-HCl, pH 7.4: 0.1%
)Tween-20; 5% nonfat dry milk , and they were then blotted
( ) ( )overnight with either COX-1 1:500 or COX-2 1:500 spe-
(cific antibodies COX-1, cat a1753; COX-2, cat a1746;
)Santa Cruz Biotechnology Inc, Santa Cruz, CA . The mem-
branes were washed in BLOTTO before a 1-hour incubation
( )with donkey anti-goat horseradish peroxidase HRP conju-
gated secondary antibody. The membranes were washed in
(TBST 0.15 mol/L NaCl; 10 mmol/L Tris-HCl, pH 7.4; 0.1%
)Tween-20 and developed using the Enhanced Chemi-
( )luminescence ECL plus chemiluminescence system
( )Amersham, Arlington Heights, IL , and then exposed to
( )Hyperfilm Amersham .
Xenograft Model of Tumor Biology
( )HCA-7 and HCT-116 ATCC aCCL 247 cells were grown
on plastic culture dishes according to standard cell culture
[ ]techniques 12 . The cells were trypsinized and resus-
( )pended in sterile phosphate buffered saline PBS and then
pelleted by brief centrifugation at 1500 rpm. The supernant
was aspirated and cells were resuspended in PBS and
counted with a hemocytometer. A final concentration of 5 =
107 cells/mL was made and 100 mL of cell suspension was
injected subcutaneously with a tuberculin syringe and a
27-gauge needle. For both HCA-7 and HCT-116 cell lines
animals were randomly divided into treatment and control
arms, with five animals in each group. In the sulindac sulfide
experiments seven animals were included in each group.
Treatment was initiated at the time the tumors were im-
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( 4 )Figure 3. HCA-7 and HCT-116 cell growth in an artificial matrix is attenuated by treatment with sulindac sulfone. HCT-116 2.5 = 10 cells /well and
( 4 ) ( ) ( )HCA-7 5 = 10 cells /well cells were grown in Matrigel containing the indicated dose of sulindac sulfide B and D , sulindac sulfone A and C , or the
solvent DMSO in triplicate. The media was replaced every other day with media containing fresh drug. After 14 days, colony counts were obtained by
( )examining 10 random fields per well A and B . Each well was photographed three times, and measurements of 10 random fields were obtained and
( )volumes calculated C and D . Error bars represent standard error of the mean.
planted with the exception of the sulindac sulfide treatment
group in which treatment was delayed until the tumor was
( )established 7 weeks . When no effect was observed on
tumor growth with sulindac sulfone treatment, the amount of
sulfone was increased until a maximal dose of 100 mg/kg
was achieved by week 5. The size of the tumor was deter-
mined at 1-week intervals by direct measurement. The
( [volume was calculated according to the equation V s L
2] )= W = 0.5 , where V s volume, L s length, and W s
[ ]width 13 .
Statistical Methods
Student’s t-test was used to determine significant differ-
ences in in vitro assays. In the xenograft experiments,
ANOVA with repeated measures was employed to evaluate
the significance of drug treatment on tumor growth.
Results
Effect of Sulindac Sulfone on Prostaglandin E Production2
in HCA-7 Cells
Sulindac sulfide, the active metabolite of sulindac, in-
hibits the enzymatic activity of recombinant COX-1 and
COX-2. It has been reported that sulindac sulfone does not
inhibit the activity of either COX isoform using recombinant
[ ]enzyme assay 7 . We confirmed this by testing the effect of
sulfone on recombinant COX activity and saw no change in
( ) ( )Figure 4. Sulindac sulfone does not alter the growth of HCA-7 or HCT-116 xenografts. HCA-7 A or HCT-116 B cells were grown to 70% confluence
and then trypsinized; 5 = 10 6 cells were injected subcutaneously into the dorsal flank of athymic mice. The mice were divided into treatment and
control groups. The initial dose of sulindac sulfone was 10 mg/kg and then increased to 100 mg/kg by week 5. The volume of the tumor was calculated
( [ 2] ) ( ) ( 6 )according to the equation V s L = W = 0.5 , where V s volume, L s length, and W s width insert . HCA-7 cells 5 = 10 cells were
xenograft into nude mice. After 7 weeks of tumor growth intraperitoneal injections with sulindac sulfide were initiated at a dose of 10 mg/kg every other
day. Tumor measurements were obtained as described.
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enzyme activity even when millimolar amounts of drug were
( )added data not shown . However, it is possible that in vitro
the sulfone derivative may affect other steps in the
eicosanoid biosynthetic pathway. Therefore, we tested
whether or not sulfone treatment altered PGE levels in a2
colorectal cancer cell line, HCA-7, which expresses high
levels of COX-2. As expected, 25 mmol/L sulfide treatment
reduced PGE levels by 95%. However, to our surprise,2
sulindac sulfone treatment also inhibited PGE production2
( )by HCA-7 cells IC s .360 mmol/L; Figure 1 . To evaluate50
whether or not the decrease in PG synthesis was limited to
PGE we tested the effect of sulfone treatment on PG2
( )production in rat intestinal epithelial RIE cells overexpress-
ing COX-2, which produce mainly prostacyclin. Levels of
6-ketoPGF a , the stable metabolite of prostacyclin, were1
measured after treatment with either sulindac sulfide or
sulfone. Sulindac sulfide at 25 mmol/L reduced 6-keto
PGF a levels by 73.5% and sulindac sulfone at 100 mmol/L1
reduced 6-ketoPGF a by 29.2%. Therefore, inhibition of PG1
production by sulindac sulfone in vitro is not specific to one
class of PGs. There was no detectable COX-1 in HCA-7
cells and neither sulindac sulfide nor sulfone affected COX-2
( )expression Figure 2 . Therefore, the decrease in PG pro-
duction did not result from alterations in steady state levels
of COX-2.
Effect of Sulindac Sulfone or Sulfide on Colorectal Cancer
Cell Colony Growth in Matrigel
Because sulindac sulfone decreased PG levels in cul-
tured HCA-7 cells we tested whether sulfone impaired the
ability of HCA-7 or HCT-116 cells to form discrete colonies
in Matrigel. HCA-7 cells express high levels of COX-2,
whereas there is no detectable COX-1 or COX-2 protein in
[ ]HCT-116 cells 12 . COX-2 selective inhibitors reduce the
growth of HCA-7 cells in Matrigel,whereas there is no effect
on the growth of HCT-116 cells. Each cell line was plated in
triplicate in Matrigel mixed with the indicated amount of
( )either sulindac sulfide, sulfone, or vehicle DMSO . Both
HCA-7 and HCT-116 cells showed equivalent reductions in
(colony number with sulfone or sulfide treatment sulfone
( )EC f50 mmol/L, sulfide EC -50 mmol/L Figure 3A ,50 50
however, HCA-7 colony size was much more sensitive than
(HCT-116 to treatment with either sulfone or sulfide Student
t-test at 25 mmol/L: sulfone, P- .01; sulfide, P- .0001;
)Figure 3C .
Treatment of COX-2–Positive and Negative Colorectal
Cancer Cell Xenografts with Sulindac Sulfone
Because sulindac sulfone inhibited the in vitro growth of
HCA-7 and HCT-116 cells, we sought to test whether sulin-
dac sulfone altered the in vivo growth of either cell line by
using a xenograft tumor model. HCA-7 or HCT-116 cells
were implanted into the dorsal flank of nude mice. We have
found that in this model NSAIDs reduce tumor growth when
given every other day at doses between 5 to 10 mg/kg.
Therefore, immediately preceding tumor cell implantation an
initial dose of 10 mg/kg of sulfone was injected intraperi-
toneally. This dose was repeated every other day, and
tumor dimensions were measured at weekly intervals as
shown in Figure 4. No effect was observed on either HCA-7
or HCT-116 tumor growth after 2 weeks of sulfone treat-
ment at this dosing regimen. Previously, we have observed
a significant difference in tumor size after 2 weeks of treat-
ment of HCA-7 xenografts with selective inhibitors of COX-2
[ ]12,14 . Therefore, the amount of sulfone was increased
until a maximal dose of 100 mg/kg was achieved by week
5. Throughout the duration of this experiment no differences
in tumor volume were observed with sulfone treatment in
either HCA-7 or HCT-116 xenografts.
A more rigorous test of the chemotherapeutic potential of
a drug is to test its effect on the growth of established
xenografts. This removes the possibility of the drug interfer-
ing with tumor implantation and directly measures the ability
of a compound to influence the growth of an established
tumor. Sulindac sulfide was used at a dose of 10 mg/kg
every other day to treat HCA-7 xenografts that had been
implanted 7 weeks earlier. In this experiment, a significant
reduction in tumor growth was observed within 2 weeks of
( )treatment initiation Figure 4A, insert .
To measure the COX expression profile of HCA-7 and
HCT-116 xenografts, tumor lysates were made and West-
ern blotting analysis was done with COX-1 or COX-2 selec-
tive antibodies. In agreement with previous reports, HCA-7
xenografts expressed COX-2 but not COX-1 protein, and
HCT-116 tumors contained neither COX-1 nor COX-2 pro-
( ) [ ]tein Figure 5 12 .
Prostaglandin Measurements in HCA-7 Xenografts
Although a significant change in tumor size was not
observed with sulfone treatment, we assessed the effect of
the sulfone on PGE production in the HCA-7 xenografts.2
PGE is the major PG produced by HCA-7 cells and is2
Figure 5. Colorectal cancer xenograft COX -1 and COX - 2 expression.
Tumor lysates from HCA-7 or HCT-116 xenografts were resolved via
SDS-PAGE. Proteins were transferred to membranes and then blotted
with either COX-1– or COX- 2–specific antisera. Fifty micrograms of
( )MC- 26 q cell lysates served as COX -1– positive controls.
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Figure 6. HCA-7 xenograft PGE levels. HCA-7 tumor PGE levels2 2
with and without sulindac sulfone treatment as determined by stable
isotope dilution techniques with gas chromatography negative ion chem-
( )ical ionization-mass spectrometry see methods .
[ ]reported to be elevated in colorectal cancers 15 . At
necropsy the tumors were assayed for PGE levels. Sulin-2
dac sulfone treatment had no effect on the PGE levels in2
( ) (either HCA-7 Figure 6 or HCT-116 xenografts data not
)shown .
Discussion
Considerable excitement has been generated about the
chemopreventative effects of NSAIDs on colorectal cancer
since Waddell and Loughry first observed that sulindac
reduced the number of rectal polyps in a patient with Gard-
[ ]ner’s syndrome 16 . Sulindac, in a controlled clinical trial,
was found to decrease the size and number of polyps in
[ ]FAP patients 17 . Unfortunately, sulindac, like most NSAIDs,
can exhibit undesirable gastrointestinal side effects.
Sulindac is a prodrug, which is reduced in vivo to sulin-
dac sulfide. Sulindac sulfide can inhibit both COX enzymes
and has been shown to have antiproliferative and proapop-
[ ]totic properties in colorectal carcinoma cells 18 . Sulindac
can also be oxidized to a sulfone derivative which also has
been reported to induce apoptosis and growth arrest in
[ ]colorectal cancer cell lines 7 . Piazza and colleagues re-
ported that sulindac sulfone treatment reduced the number
[ ]of adenomas and carcinomas in the AOM-treated rat 8 .
However, in another animal model of colorectal cancer, the
APC mutant Min mouse, sulindac sulfone was ineffective at
[ ]reducing tumor multiplicity 4 . Both AOM rat and Min mouse
studies were designed to test the ability of the sulfone
derivative to prevent tumor growth in a setting in which
normal epithelium is induced to a transformed state by
either carcinogen exposure or by the presence of a preexist-
ing genetic mutation. In this study, we tested the effect of
sulfone treatment on the growth of colorectal cancer cells by
using both in vitro and in vivo growth assays. We have
previously found that selective COX-2 inhibitors block tumor
growth in this model.
We found that sulindac sulfone did not modify the growth
of colorectal cancer cells xenografted into nude mice. In
order to control the dose given to individual animals and to
increase the likelihood that sulfone would enter the circula-
tion and thus reach the tumor site, we chose to deliver the
drug by intraperitoneal injection. There was no effect on
tumor growth observed in either HCA-7 or HCT-116
xenografts, even when doses of 100 mg/kg were given. In
humans, sulindac sulfide has a serum half-life of 13 to 14
hours, and sulindac sulfone has a longer serum half-life of
[ ]20 to 22 hours 19,20 , suggesting that differences in the
chemotherapeutic potential of these compounds is not due
to rapid clearance of sulindac sulfone. Furthermore, similar
studies with selective inhibitors of COX-2 such as SC-58125
or meloxicam at 7.5 mg/kg and 40 mg/kg, respectively,
inhibited tumor growth within 2 weeks of starting treatment
[ ]12,14 . Additionally, sulindac sulfide effectively inhibited
tumor growth within 2 weeks of initiating treatment.
An alternative explanation for sulindac sulfone’s lack of
an effect on tumor growth may be a requirement for gut
specific cofactors in order for an antineoplastic effect in
vivo. However, sulindac sulfone is able to induce apoptosis
and inhibit the in vitro growth of colorectal cancer cells
[ ]7,21 in the absence of gut-derived cofactors and sulindac
sulfone is effective at inhibiting the in vitro and in vivo
[ ]growth of nongastrointestinal-derived cancers 22 . Further-
more, sulindac sulfone has no effect on tumor growth in the
Min mouse. In this model the tumors arise in the gastro-
intestinal tract and are exposed to luminal contents during
drug treatment.
In agreement with previous reports, by using in vitro
growth assays, we found that sulindac sulfone could inhibit
the growth of HCA-7 and HCT-116 cells. We observed a
decrease in both the size and number of HCA-7 colonies
grown in artificial matrix, suggesting that sulindac sulfone
inhibits colony formation and alters the growth character-
istics of surviving colonies, possibly by altering the balance
between cell proliferation and programmed cell death.
If sulindac sulfone does not directly inhibit the activity of
recombinant COX, then why is a reduction in PGs observed
when HCA-7 cells are treated with sulindac sulfone? It is
possible that sulfone treatment could affect the activity of
PG synthases, but this seems unlikely because sulindac
sulfone also inhibited the production of prostacyclin in
RIE-COX-2 cells and PGE by RKO cells transiently trans-2
( )fected with rat COX-2 data not shown . Decreasing the
steady state levels of COX-2 in HCA-7 cells could result in
decreased PG production. We determined by Western blot-
ting that sulindac sulfone did not influence either COX-1 or
COX-2 protein levels in HCA-7 cells. It has been reported
(that sulindac sulfone can inhibit phospholipase A 15% at2
) [ ]0.1 - 1000 mmol/L 8 . In our experiments, we added
exogenous arachidonate to the cell culture media 1 hour
before obtaining samples for PG determination; it is unlikely
that inhibition of PLA activity by sulindac sulfone could2
affect PG production under these circumstances.
Why does sulindac sulfone inhibit colorectal cancer cell
growth in in vitro assays and yet have no effect on the
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growth of the cells in the tumor xenograft model? Tumor
xenograft assays evaluate a compound’s effectiveness in
the setting of whole animal physiology. Clearance, bioavail-
ability, and biotransformation may attenuate or amplify a
compound’s effect on the tumor’s biological characteristics.
Furthermore, in vivo assays test the ability of a compound
to inhibit tumor growth in an environment where tumor/
stromal interactions are occurring. It is possible that the
( )pathway or pathway s by which sulfone inhibits the growth
of HCA-7 and HCT-116 cells in vitro are compensated for
by stromal- derived signals present in an in vivo system.
The effectiveness of sulindac sulfone treatment on in
vivo tumor growth is questionable. Sulindac sulfone has
been reported to be effective at reducing the tumor burden
[ ]in the AOM rat model 8 and in the MNU-induced mammary
[ ]tumor model 23 . However, in these reports, there were
decreases in weight gain with sulindac sulfone treatment. It
is possible that the decrease in weight gain during treatment
may contribute to the reduction in tumor number in these
[ ]models 24,25 . Furthermore, sulindac sulfone was ineffec-
tive at inhibiting polyp formation in the Min mouse model
[ ]4 . These studies were designed to test sulfone’s effective-
ness at preventing tumor formation. In this report, we deter-
mined that sulindac sulfone inhibited colorectal cancer cell
growth in vitro with an associated reduction in PG produc-
tion, but sulindac sulfone treatment did not alter the growth
characteristics of colorectal cancer xenografts in vivo. Hu-
man clinical chemoprevention trials evaluating sulindac sul-
( )fone FGN-1 are underway. These trials should provide
definitive evidence about the usefulness of sulindac sulfone
as a chemoprotective agent.
Acknowledgements
We thank Amit Kalgutkar and John Plastaras for their assis-
tance with verifying the purity of the sulindac derivatives and
for prostanoid assays. HCA-7 cells were a generous gift
from Susan Kirkland.
This work was supported in part by United States Public
( )Health Services Grants DK 47297-OlAl R.N.D. , 5P030
( )ES-00267-29, CA68485-04 R.N.D. , DK48831, and
( )GM15431 J.D.M. . R.N.D. is a recipient of a VA Research
Merit Grant and the Mina C. Wallace Professor of Gastroen-
terology and Cancer Prevention. The T.J. Martell Founda-
tion also provided support for this research project.
References
[ ] ( )1 Thun MJ, Namboodiri MM, and Heath CWJ 1991 . Aspirin use and reduced
risk of fatal colon cancer. N Engl J Med 325, 1593-1596.
[ ]2 Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, and Willett
( )WC 1994 . Aspirin use and the risk for colorectal cancer and adenoma in
male health professionals. Ann Intern Med 121, 241-246.
[ ]3 Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P,
( )Booker SV, Robinson CR, and Offerhaus GJ 1993 . Treatment of colonic and
rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J
Med 328, 1313-1316.
[ ]4 Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci
( )C, Newmark HL, Chadburn A, and Bertagnolli MM 1998 . The sulfide metabo-
lite of sulindac prevents tumors and restores enterocyte apoptosis in a murine
model of familial adenomatous polyposis. Carcinogenesis 19, 87-91.
[ ] ( )5 Samaha HS, Kelloff GJ, Steele V, Rao CV, and Reddy BS 1997 . Modulation
of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phen-
ylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemo-
prevention and promotion. Cancer Res 57, 1301-1305.
[ ]6 Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B,
( )and Kinzler KW 1996 . Sulindac suppresses tumorigenesis in the min mouse.
Carcinogenesis 17, 1757-1760.
[ ]7 Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, and
( )Ahnen DJ 1997 . Apoptosis primarily accounts for the growth-inhibitory prop-
erties of sulindac metabolites and involves a mechanism that is independent of
cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57,
2452-2459.
[ ]8 Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C,
Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie, J, Burt RW, Ellsworth L,
( )Ahnen DJ, and Pamukcu R 1997 . Sulindac sulfone inhibits azoxymethane-in-
duced colon carcinogenesis in rats without reducing prostaglandin levels.
Cancer Res 57, 2909-2915.
[ ]9 Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ,
( )DuBois RN, Jetton T, and Morrow J 1997 . EGF receptor activation induces
nuclear targeting of COX-2, basolateral release of prostaglandins and mitoge-
nesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 94, 657-662.
[ ] ( )10 DuBois RN, Awad J, Morrow J, Roberts LJ, and Bishop PR 1994 . Regulation
of eicosanoid production and mitogenesis in rat intestinal epithelial cells by
transforming growth factor-a and phorbol ester. J Clin Invest 93, 493-498.
[ ] ( )11 DuBois RN, Shao J, Sheng H, Tsujii M, and Beauchamp RD 1996 . G1 delay
in intestinal epithelial cells overexpressing prostaglandin endoperoxide syn-
thase-2. Cancer Res 56, 733-737.
[ ]12 Sheng H, Shao J, Kirkland SC, Isakson P, Coffey R, Morrow J, Beauchamp
( )RD, and DuBois RN 1997 . Inhibition of human colon cancer cell growth by
selective inhibition of cyclooxygenase-2. J Clin Invest 99, 2254-2259.
[ ]13 Wang JL, Sun L, Myeroff X, Wang LE, Gentry J, Yang J, Liang E, Zborowska
( )S, Markowitz JK, Willson, and Brattain MG 1995 . Demonstration that muta-
tion of the type II transforming growth factor beta receptor inactivates its tumor
suppressor activity in replication error-positive colon carcinoma cells. J Biol
Chem 270, 22044-22049.
[ ]14 Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M,
( )Morrow JD, and DuBois RN 1998 . Meloxicam inhibits the growth of colorectal
cancer cells. Carcinogenesis.
[ ] ( )15 Rigas B, Goldman IS, and Levine L 1993 . Altered eicosanoid levels in human
colon cancer. J Lab Clin Med 122, 518-523.
[ ] ( )16 Waddell WR, and Loughry RW 1983 . Sulindac for polyposis of the colon. J
Surg Oncol 24, 83-87.
[ ]17 Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P,
( )Booker SV, Robinson CR, and Offerhaus GJ 1993 . Treatment of colonic and
rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J
Med 328, 1313-1316.
[ ]18 Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, and
( )Rigas B 1996 . Effects of nonsteroidal anti-inflammatory drugs on proliferation
and on induction of apoptosis in colon cancer cells by a prostaglandin-
independent pathway. Biochem Pharmacol 52, 237-245.
[ ] ( )19 Ravis WR, Diskin CJ, Campagna KD, Clark CR, and McMillian CL 1993 .
Pharmacokinetics and dialyzability of sulindac and metabolites in patients with
end-stage renal failure. J Clin Pharmacol 33, 527-534.
[ ] ( )20 Strong HA, Warner NJ, Renwick AG, and George CF 1985 . Sulindac
metabolism: the importance of an intact colon. Clin Pharmacol Ther 38,
387-393.
[ ]21 Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel
( )K, Burt RW, Alberts DS, Pamukcu R, et al. 1995 . Antineoplastic drugs
sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer
Res 55, 3110-3116.
[ ]22 Thompson HJ, Jiang C, Lu JX, Mehta RG, Piazza GA, Paranka NS, Pamukcu
( )R, and Ahnen DJ 1997 . Sulfone metabolite of sulindac inhibits mammary
carcinogenesis. Cancer Res 57, 267-271.
[ ]23 Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu
( )R, and Ahnen DJ 1997 . Sulfone metabolite of sulindac inhibits mammary
carcinogenesis. Cancer Res 57, 267-271.
[ ] ( )24 Reddy BS, Wang CX, and Maruyama H 1987 . Effect of restricted caloric
intake on azoxymethane-induced colon tumor incidence in male F344 rats.
Cancer Res 47, 1226-1228.
[ ] ( )25 Kumar SP, Roy SJ, Tokumo K, and Reddy BS 1990 . Effect of different levels
of calorie restriction on azoxymethane- induced colon carcinogenesis in male
F344 rats. Cancer Res 50 , 5761-5766.
Neoplasia v Vol. 1, No. 2, June 1999
